ACKNOWLEDGEMENTS
The trial was partially funded by a National Cancer Institute (NCI)
Cancer Therapy Evaluation Program (CTEP) PBTC U01 Grant: 2UM1CA081457
(UM1). The content is solely the responsibility of the authors and does
not necessarily represent the official views of the National Institutes
of Health. Partial funding was also provided by MSKCC Core Grant (P30
CA008748) and by the American Lebanese Syrian Associated Charities
(ALSAC) which provides funding and infrastructure support for the PBTC
Operations Core personnel. Pfizer provided Palbociclib and financial
support for trial conduct, patient research costs, operations costs and
correlative studies. Pfizer reviewed the manuscript but did not have a
direct role in trial design, patient recruitment, data collection,
analyses or manuscript preparation.